Hormone Ablation Therapy (Including Intermittent) In Patients With Prostate Cancer
September 21st, 2008 Posted in hormone therapyDr. Kurt Miller, Professor of Urology at Univsitätsmedizin, Berlin, presented the use of androgen deprivation therapy in patients with prostate cancer. He presented the results of a randomized prospective trial, (AU0 AP 17/95), comparing intermittent and continuous androgen suppression in advanced prostate cancer.
Between 10/97 and 6/06, 335 patients were randomized. Among those with M (+) disease to bone, 41% with a median PSA of 158 ng/ml were randomized to intermittent therapy and 35% with a median PSA of 139 ng/ml were randomized to continuous androgen deprivation.
Dr. Miller indicated that, in his opinion, the ideal candidate for intermittent androgen deprivation therapy presents with low volume disease, a rising PSA, and documented progression after discontinuation of adjuvant hormonal therapy. In the presence of metastatic disease, Dr. Miller noted that all patients should have a PSA nadir <4 ng/ml on their first androgen deprivation induction.